Pralsetinib’s implementation price in 2025 and reasons for price adjustment

Platinib is a selective RET tyrosine kinase inhibitor, mainly used for the treatment of RET fusion-positive non-small cell lung cancer and other solid tumors. In China, the original drug Platinib is already on the market, but it has not yet been included in the medical insurance system, so patients need to bear all costs. Common packaging specifications include 100 mg 60 tablets and 100 mg 120 tablets. The price is relatively high. A box may cost more than 20,000 yuan. In some areas, the price is even as high as 60,000 yuan. This reflects the impact of drug supply, demand and channel factors on the price in the early stages of marketing.

The original drug Platinib is more expensive in overseas markets. The price of a box of 60 tablets fluctuates between 40,000 and more than 100,000 yuan. This is closely related to the research and development costs, registration approval and market pricing strategies of the original drug. In order to meet the needs of patients in different regions, some overseas markets have launched generic drugs. The ingredients of the drugs are basically the same as the original drugs, but the price is significantly lower. For example, the 120 generic drugs produced in Laos only cost more than 3,000 yuan, providing patients with a more economical choice.

The implementation price of platinib in China is affected by multiple factors, including import costs, production and transportation costs, channel distribution costs, and drug scarcity. In the pricing process, pharmaceutical companies will also consider the clinical efficacy advantages, indication coverage and patient payment ability of the drug to set a reasonable market price. At the same time, regional differences in prices may also fluctuate due to hospital procurement strategies, local medical insurance policies or drug supply conditions.

In the future, as competition in the domestic drug market intensifies, overseas generic drugs enter the domestic market, and medical insurance negotiations and policy adjustments advance, the price of Platinib may decline to a certain extent. The reasons for price adjustments mainly include drug cost optimization, the results of negotiations on medical insurance inclusion, and the market impact of generic drugs. Patients should pay attention to the latest price information from formal channels before purchasing, and make reasonable arrangements for medication based on doctor's guidance and financial status to ensure continuity of treatment and affordability.

Reference link:https://www.drugs.com